| Budget Amount *help |
¥4,160,000 (Direct Cost: ¥3,200,000、Indirect Cost: ¥960,000)
Fiscal Year 2013: ¥1,950,000 (Direct Cost: ¥1,500,000、Indirect Cost: ¥450,000)
Fiscal Year 2012: ¥2,210,000 (Direct Cost: ¥1,700,000、Indirect Cost: ¥510,000)
|
|---|
| Research Abstract |
CD4+CD25+Foxp3+ regulatory T cell (Treg) has a central role in maintaining immune tolerance and interleukin-2 (IL-2) is critical for Treg growth, survival and activity. We reported that administration of low-dose IL-2 could preferentially enhance Treg in vivo and suppress clinical manifestations of chronic GVHD after allogeneic hematopoietic stem cell transplantation, suggesting the therapeutic potential of low-dose IL-2 to reconstruct immune tolerance in vivo. Our murine experiments of low-dose IL-2 therapy demonstrated that in vivo effect of exogenous IL-2 is susceptible to several external factors, including the host immune status and the dose or timing of IL-2 administration. These findings will be important information to explore the individualized IL-2 therapy that enables to standardize and optimize this cytokine therapy.
|
